<p>Shanghai Henlius Biotech Inc. announced that the National Medical Products Administration has approved the application for a clinical trial of HLX43 for injection, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07 (a recombinant anti-EGFR humanised monoclonal antibody injection) and HANSIZHUANG (serplulimab injection) for the treatment of advanced solid tumours. According to the company, as of the date of the announcement, no similar combination therapy has been approved for marketing globally. The company cautioned that there is no guarantee of successful development or commercialisation of HLX43 and HLX07. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260127-12002326), on January 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

<p>Shanghai Henlius Biotech Inc. has received approval from the National Medical Products Administration for a clinical trial of HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07 and HANSIZHUANG for treating advanced solid tumours. This combination therapy is unique as no similar treatment has been approved globally. However, the company warns that successful development or commercialization of these therapies is not guaranteed.</p>

Reuters

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Research Sector 100 ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

HENLIUS

Henlius Biotech Wins Approval for Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours